Instrumentation posts loss as it rebuilds in Italy:
This article was originally published in Clinica
Executive Summary
Instrumentation Laboratory saw its losses continue in the first half of this year. Its sales fell to Lit212 billion ($123 million) from Lit228 billion. While it made a slightly smaller net loss for the half (Lit7 billion compared with Lit9 billion), the company expects poor trading conditions to continue to affect its margins. The Milan-based company said that competitive pressures in Italy, an unfavourable product mix and its attempt to rebuild its sales staff all contributed to the malaise.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.